Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

Yi Cai; Sonam Dodhia; Gloria H. Su

doi:10.18632/oncotarget.14729

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

Yi Cai, Sonam Dodhia and Gloria H. Su _

PDF | HTML | How to cite

Oncotarget. 2017; 8:22203-22217. https://doi.org/10.18632/oncotarget.14729

Metrics: PDF 2538 views | HTML 3555 views | ?

Abstract

Yi Cai1, Sonam Dodhia1 and Gloria H. Su1,2,3

1 Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York, NY, USA

2 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA

3 Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA

Correspondence to:

Gloria H. Su, email:

Keywords: PI3K signaling, head and neck squamous cell carcinoma, PIK3CA mutation, PI3K inhibitor, personalized medicine

Received: October 15, 2016 Accepted: January 09, 2017 Published: January 18, 2017

Abstract

The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14729

Publication Alerts

Reviews:

Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

Abstract